Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting
I'm PortAI, I can summarize articles.
Annovis Bio Inc. will present Phase 3 data on buntanetap's effects in Parkinson’s disease dementia at the 2025 Parkinson Study Group Annual Meeting in San Diego. The presentation, led by CEO Maria Maccecchini, will focus on cognitive outcomes and biomarker improvements. The event is scheduled for December 5 at 6:15 p.m. PST.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments